MiR-514 Attenuates Proliferation and Increases Chemoresistance by Targeting ATP Binding Cassette Subfamily in Ovarian Cancer

Overview

Journal Mol Genet Genomics

Specialty Genetics

Date 2018 May 13

PMID 29752546

Citations 17

Authors

Sha Xiao

Ming Zhang

Chang Liu

Deling Wang

Affiliations

Soon will be listed here.

Abstract

Cisplatin is one of the most popular chemotherapeutic drugs in treating ovarian cancer. Resistance to cisplatin is a common clinical challenge that needs to be solved to increase its anti-tumor effects. The relation of miR-514 expression with prognosis in ovarian cancer patients was analyzed based on GSE73584 datasets. The regulation of miR-514 on proliferation and cisplatin chemosensitivity of ovarian cells was examined by MTT assay, colony-formation assay and soft-agar colony-formation assay. Dual luciferase assay was performed to detect the direct interaction of miR-514 with its downstream targets. Immunobloting and qRT-PCR were performed for target gene expression analysis. Low expression of miR-514 was related to poor prognosis in ovarian cancer patients. MiR-514 repressed proliferation and decreased cisplatin chemosensitivity in ovarian cancer cells by targeting ATP binding cassette subfamily. MiR-514 is of clinically significance in ovarian cancer by attenuating proliferation of ovarian cancer cells and decreasing chemoresistance of cisplatin by targeting ATP binding cassette subfamily.

Citing Articles

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.

Nunes M, Bartosch C, Abreu M, Richardson A, Almeida R, Ricardo S Cells. 2024; 13(9.

PMID: 38727322 PMC: 11083313. DOI: 10.3390/cells13090786.

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.

Alam S, Giri P Cancer Drug Resist. 2024; 7:6.

PMID: 38434767 PMC: 10905178. DOI: 10.20517/cdr.2023.152.

Nucleolar protein TAAP1/ confers pro-survival signaling in non-small cell lung cancer.

Doring M, Brux M, Paszkowski-Rogacz M, Guillem-Gloria P, Buchholz F, Pisabarro M Life Sci Alliance. 2024; 7(4).

PMID: 38228372 PMC: 10791977. DOI: 10.26508/lsa.202302257.

Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.

Havasi A, Cainap S, Havasi A, Cainap C Medicina (Kaunas). 2023; 59(3).

PMID: 36984544 PMC: 10057458. DOI: 10.3390/medicina59030544.

miR-514a promotes neuronal development in human iPSC-derived neurons.

Akaba Y, Takahashi S, Suzuki K, Kosaki K, Tsujimura K Front Cell Dev Biol. 2023; 11:1096463.

PMID: 36824367 PMC: 9941156. DOI: 10.3389/fcell.2023.1096463.

References

Jung Y, Kim H, Seo S, Choi Y, Nam E, Kim S . Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines. Yonsei Med J. 2015; 57(1):33-40. PMC: 4696969. DOI: 10.3349/ymj.2016.57.1.33. View

. Proceedings of the Conference on Antilymphocyte Serum, Brook Lodge, Augusta, Michigan, May 2-3, 1969. Fed Proc. 1970; 29(1):93-229. View

Horibata S, Vo T, Subramanian V, Thompson P, Coonrod S . Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells. J Vis Exp. 2015; (99):e52727. PMC: 4542786. DOI: 10.3791/52727. View

Xu Y, Miao C, Jin C, Qiu C, Li Y, Sun X . SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer. Exp Cell Res. 2018; 363(2):160-170. DOI: 10.1016/j.yexcr.2017.12.029. View

Buechler C, Eisinger K, Krautbauer S . Diagnostic and prognostic potential of the macrophage specific receptor CD163 in inflammatory diseases. Inflamm Allergy Drug Targets. 2013; 12(6):391-402. DOI: 10.2174/18715281113126660060. View

Lou H, Dean M . Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene. 2007; 26(9):1357-60. DOI: 10.1038/sj.onc.1210200. View

Liu J, Bi J, Li Z, Li Z, Liu X, Kong C . miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells. Int J Mol Med. 2018; 41(3):1765-1773. DOI: 10.3892/ijmm.2018.3374. View

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M . Cancer statistics, 2003. CA Cancer J Clin. 2003; 53(1):5-26. DOI: 10.3322/canjclin.53.1.5. View

Saed G, Fletcher N, Diamond M, Morris R, Gomez-Lopez N, Memaj I . Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target. Gynecol Oncol. 2018; 148(3):567-575. DOI: 10.1016/j.ygyno.2017.12.018. View

10.

Franken N, Rodermond H, Stap J, Haveman J, van Bree C . Clonogenic assay of cells in vitro. Nat Protoc. 2007; 1(5):2315-9. DOI: 10.1038/nprot.2006.339. View

11.

Kanaji N, Kamitori K, Hossain A, Noguchi C, Katagi A, Kadowaki N . Additive antitumour effect of D‑allose in combination with cisplatin in non-small cell lung cancer cells. Oncol Rep. 2018; 39(3):1292-1298. DOI: 10.3892/or.2018.6192. View

12.

Lee S, Choi E, Jin C, Kim D . Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005; 97(1):26-34. DOI: 10.1016/j.ygyno.2004.11.051. View

13.

Wu D, Lu P, Mi X, Miao J . Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Arch Gynecol Obstet. 2018; 297(3):699-707. DOI: 10.1007/s00404-018-4649-0. View

14.

Todorovic L, Stanojevic B, Mandusic V, Petrovic N, Zivaljevic V, Paunovic I . Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters. Med Oncol. 2018; 35(2):17. DOI: 10.1007/s12032-017-1066-3. View

15.

Friedlander M . Prognostic factors in ovarian cancer. Semin Oncol. 1998; 25(3):305-14. View

16.

Wang Z, Wang W, Huang K, Wang Y, Li J, Yang X . MicroRNA-34a inhibits cells proliferation and invasion by downregulating Notch1 in endometrial cancer. Oncotarget. 2018; 8(67):111258-111270. PMC: 5762319. DOI: 10.18632/oncotarget.22770. View

17.

Lin C, Xie L, Lu Y, Hu Z, Chang J . miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. Int J Mol Med. 2018; 41(4):2050-2058. PMC: 5810210. DOI: 10.3892/ijmm.2018.3382. View

18.

Yang X, Fraser M, Moll U, Basak A, Tsang B . Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 2006; 66(6):3126-36. DOI: 10.1158/0008-5472.CAN-05-0425. View

19.

Donninger H, Bonome T, Radonovich M, Pise-Masison C, Brady J, Shih J . Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. 2004; 23(49):8065-77. DOI: 10.1038/sj.onc.1207959. View

20.

. Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. PLoS One. 2018; 13(1):e0191454. PMC: 5766248. DOI: 10.1371/journal.pone.0191454. View